JAC Advance Access published online on July 14, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh366
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
* To whom correspondence should be addressed. E-mail: mdohmd{at}snu.ac.kr.
Objective: To determine the impact of delayed treatment of methicillin-resistant Staphylococcus aureus bacteraemia (MRSA bacteraemia) on mortality. Patients and methods: We used two different and complementary approaches: a retrospective cohort study and a matched case-control study. Of the total of all patients with S. aureus bacteraemia in a tertiary hospital over a 4 year period, 127 patients with MRSA bacteraemia were enrolled in the cohort study. The cases for the case-control study were defined as patients who received appropriate empirical treatment for MRSA bacteraemia; the controls, who were patients who received inappropriate empirical treatment for MRSA bacteraemia, were selected according to the matching variables of age, sex, severity of underlying illness, classification of main underlying disease and prior hospital stay. On the 14-point matching scale that was used to select the best controls, the average score (±S.D.) of the 30 controls was 11.2 (±2.0). Results: In the cohort study, the difference in S. aureus bacteraemia-related mortality between appropriate (30%, 9/30) and inappropriate (39%, 38/97) empirical treatment was not significant (P=0.36). In addition, multivariate analysis did not indicate that inappropriate empirical treatment was associated with mortality when independent predictors for mortality were considered (adjusted OR 1.1, 95% CI 0.4-3.1). In the case-control study, S. aureus bacteraemia-related mortality in case patients was 30% (9/30) and in control patients 33% (10/30) (P>0.99, McNemar's test). In four of the nine discordant pairs, the case patients died whereas the control patients lived. Conclusions: Our data suggest that an initial delay of 2 days in the use of appropriate antibiotics, especially of vancomycin or other glycopeptides, before the preliminary microbiological report may not adversely affect the outcome in patients with MRSA bacteraemia.
Revised May 25, 2004
Accepted June 15, 2004
Original article
Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia
2 Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
3 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
4 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. K. Gould, R. Brindle, P. R. Chadwick, A. P. Fraise, S. Hill, D. Nathwani, G. L. Ridgway, M. J. Spry, R. E. Warren, and on behalf of the MRSA Working Party of the British Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom J. Antimicrob. Chemother., May 1, 2009; 63(5): 849 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan and on behalf of the BSAC Working Parties on Resistanc Clinical implications of antimicrobial resistance for therapy J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii105 - ii114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Lin, R. A. Weinstein, and B. Hota Delay of Active Antimicrobial Therapy and Mortality among Patients with Bacteremia: Impact of Severe Neutropenia Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3188 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Kim, K.-H. Kim, H.-B. Kim, N.-J. Kim, E.-C. Kim, M.-d. Oh, and K.-W. Choe Outcome of Vancomycin Treatment in Patients with Methicillin-Susceptible Staphylococcus aureus Bacteremia Antimicrob. Agents Chemother., January 1, 2008; 52(1): 192 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Baranwal, S. C. Singhi, and M. Jayashree A 5-year PICU Experience of Disseminated Staphylococcal Disease, Part 2: Management, Critical Care Needs and Outcome J Trop Pediatr, August 1, 2007; 53(4): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gemmell, D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, R. E. Warren, and on behalf of the Joint Working Party of the Britis Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., April 1, 2006; 57(4): 589 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-T. Fang, W.-Y. Shau, P.-R. Hsueh, Y.-C. Chen, J.-T. Wang, C.-C. Hung, L. Y. L. Huang, and S.-C. Chang Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome J. Antimicrob. Chemother., March 1, 2006; 57(3): 511 - 519. [Abstract] [Full Text] [PDF]
|
|